Bristol-Myers’ nivolumab grabs its sixth breakthrough designation as new links to autoimmune diseases creep up
This morning the FDA handed out its 6th “breakthrough” drug designation for Bristol-Myers Squibb’s Opdivo (nivolumab), signaling once again the agency will continue to facilitate the checkpoint inhibitor’s rapid rollout in the oncology market.
Checkpoint inhibition has become BMS’ specialty, zipping ahead of Merck’s Keytruda (pembrolizumab) in the PD-1 arena as physicians glom on to this new treatment paradigm for orchestrating an immune system assault on cancer cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.